Table 3.
Clinical trials about using probiotics to regulate gut microbiota for COVID-19 treatment and COVID-19 vaccination efficacy.
| Identifier | Country/location | Intervention | Study design | Main aim |
|---|---|---|---|---|
| NCT04366089 | Italy | Probiotic | Parallel assignment | Treatment COVID-19 |
| NCT04366180 | Spain | Probiotic | Parallel assignment | Treatment COVID-19 |
| NCT04399252 | Unit States | Probiotic | Parallel assignment | Treatment COVID-19 |
| NCT04420676 | Austria | Synbiotic | Parallel assignment | Treatment COVID-19 |
| NCT04980560 | Prince of Wales Hospital, Hong Kong | Probiotic | An observation study | Compare microbiome profile in subjects with different COVID-19 vaccination and subjects recovered from COVID-19 |
| NCT04884776 | Prince of Wales Hospital, Hong Kong | 3Bifidobacteria at 2 × 1,010 CFU for 12 weeks | Parallel assignment | Restore gut microbiota to increase COVID-19 vaccine efficacy and reduce side-effects |
| NCT04798677 | Hospital Mare de Déu de la Merc, Spain | ABBC1 including beta-glucans, Inactivated saccharomyces cerevisae, Selenium, and Zinc | Parallel assignment | Enhance immune responses including generation of T cells, IgM and IgG |